Dupilumab for Moderate-to-Severe Atopic Dermatitis

Skin Therapy Letter-Family Practice Edition

Ramya Vangipuram¹  Stephen K. Tyring¹ 

[1] 1Center for Clinical Studies, Houston, TX, USA . 2Department of Dermatology, University of Texas Health Sciences Center, Houston, TX, USA 

关键词: atopic dermatitis;    biologics;    dupilumab;    eczema;    Th2 related inflammation;   

学科分类：医学（综合）

来源: Skin Therapy Letter-Family Practice Edition

【 摘 要 】

Atopic dermatitis (AD) is the most common chronic inflammatory disease affecting 2-10% of adults and up to 15-30% of children. Despite a rising prevalence, effective and safe therapeutics for patients with moderate-to-severe AD are limited due to toxicity and side effects. Dupilumab, an interleukin (IL)-4 and IL-13 antagonist that limits type 2 T helper (Th2) driven inflammatory activity, is a promising therapeutic option. In clinical trials, it has demonstrated efficacy by reducing clinical activity and symptoms, and showed improvement in the AD genomic phenotype, including a significant reduction in Th2 chemokines and reversal of key epidermal markers of AD. It also has a favorable safety profile. This review discusses the role of dupilumab in treating Th2 related inflammation, and its efficacy and safety, as demonstrated in clinical trials. Dupilumab (Dupixent®) recently gained US FDA approval for patients with moderate-to-severe AD, and is poised to revolutionize the management of this chronic, relapsing condition. 

【 授权许可】

CC BY